Literature DB >> 14514374

[Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma and their correlation with prognosis].

Yu-xin Wu1, Jing-hua Wang, Hua Wang, Xin-yun Yang.   

Abstract

OBJECTIVE: To assess the correlation between expression of proliferation antigen Ki-67, early apoptotic protein M30 (M30CytoDEATH, CK18) and biologic characteristics in endometrial carcinoma.
METHODS: SP immunohistochemical technique was used to detect the expression of Ki-67 and M30 in 79 cases of endometrial carcinoma respectively.
RESULTS: The mean Ki-67 indices varied with histological grading and clinical stage of the tumor, being 20.48 +/- 14.86 in grade 1, 24.12 +/- 14.42 in grade 2 and 38.84 +/- 11.88 in grade 3; 20.65 +/- 13.56 in stage I; 26.92 +/- 14.71 in stage II; and: 35.14 +/- 14.70 in stage III. The mean M30 indices varied with the grading and stage of the tumor, being 1.03 +/- 1.42 in grade 1, 1.03 +/- 1.64 in grade 2 and 1.94 +/- 1.20 in grade 3; 0.30 +/- 0.58 in stage I; 1.66 +/- 1.74 in stage II; and 2.07 +/- 1.62 in stage III.
CONCLUSIONS: Ki-67 and M30 indexes are significantly correlated with biologic behavior and prognosis in endometrial carcinoma. There is a positive relationship between Ki-67 and M30 indexes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514374

Source DB:  PubMed          Journal:  Zhonghua Bing Li Xue Za Zhi        ISSN: 0529-5807


  8 in total

1.  MicroRNA signatures differentiate uterine cancer tumor subtypes.

Authors:  Elena S Ratner; David Tuck; Christine Richter; Sunitha Nallur; Rajeshvari M Patel; Vince Schultz; Pei Hui; Peter E Schwartz; Thomas J Rutherford; Joanne B Weidhaas
Journal:  Gynecol Oncol       Date:  2010-06-09       Impact factor: 5.482

2.  Serum cytokeratin 18 as a biomarker for gastric cancer.

Authors:  Katsunobu Oyama; Sachio Fushida; Jun Kinoshita; Koichi Okamoto; Isamu Makino; Keishi Nakamura; Hironori Hayashi; Masafumi Inokuchi; Hisatoshi Nakagawara; Hidehiro Tajima; Hideto Fujita; Hiroyuki Takamura; Itasu Ninomiya; Hirohisa Kitagawa; Takashi Fujimura; Tetsuo Ohta
Journal:  Clin Exp Med       Date:  2012-07-24       Impact factor: 3.984

3.  Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls.

Authors:  Basak Oven Ustaalioglu; Ahmet Bilici; Serif Ercan; Asuman Orcun; Mesut Seker; Alper Ozkan; Recep Ustaalioglu; Mahmut Gumus
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

4.  Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma.

Authors:  Fatma Sen; Ibrahim Yildiz; Hatice Odabas; Makbule Tambas; Leyla Kilic; Ahmet Karadeniz; Musa Altun; Meltem Ekenel; Murat Serilmez; Derya Duranyildiz; Sevil Bavbek; Mert Basaran
Journal:  Tumour Biol       Date:  2014-10-18

5.  The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer.

Authors:  Bala Basak Oven Ustaalioglu; Ahmet Bilici; Serif Ercan; Mesut Seker; Asuman Orcun; Mahmut Gumus
Journal:  Med Oncol       Date:  2013-03-28       Impact factor: 3.064

6.  Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients.

Authors:  Engin Ulukaya; Esra Karaagac; Ferda Ari; Arzu Y Oral; Saduman B Adim; Asuman H Tokullugil; Türkkan Evrensel
Journal:  Radiol Oncol       Date:  2011-03-15       Impact factor: 2.991

Review 7.  New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma.

Authors:  Leonardo Lorente
Journal:  World J Gastroenterol       Date:  2018-10-07       Impact factor: 5.742

8.  Prognostic Value of Serum Caspase-Cleaved Cytokeratin-18 Levels before Liver Transplantation for One-Year Survival of Patients with Hepatocellular Carcinoma.

Authors:  Leonardo Lorente; Sergio T Rodriguez; Pablo Sanz; Antonia Pérez-Cejas; Javier Padilla; Dácil Díaz; Antonio González; María M Martín; Alejandro Jiménez; Manuel A Barrera
Journal:  Int J Mol Sci       Date:  2016-09-09       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.